Biotechnology play NSL Health Ltd jumped 20 per cent yesterday to 35¢, but market observers are uncertain what is behind the surge in the company's fortunes.

NSL owns the rights to a diagnostic tool that would allow general practitioners to test patients for allergies themselves, rather than referring them to a specialist. The tool is both less complicated and expensive than current techniques.